Patients with hemophilia A benefit from preventive use of newer FDA-approved extended half-life therapies - WWSB https://t.co/VdVCvDhg3U
— IDRO (@IDROOhio) March 27, 2019
from Twitter https://twitter.com/IDROOhio
March 27, 2019 at 02:11AM
Wednesday, March 27, 2019
Patients with hemophilia A benefit from preventive use of newer FDA-approved extended half-life therapies - WWSB https://t.co/VdVCvDhg3U
from Twitter https://twitter.com/IDROOhio
March 27, 2019 at 02:11AM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment